CAS: 5271-67-0; 2-Thiophenecarbonyl Chloride

上下游产品

CAS号527-72-0 2-噻吩甲酸 | CAS号3437-95-4 2-碘噻吩 | CAS号201230-82-2 carbon monoxide | CAS号5380-42-7 2-噻吩甲酸甲酯 | CAS号39880-77-8 N-甲基-(6ci,7ci,9... | CAS号71267-32-8 N-methylthiophe... | CAS号33311-43-2 potassium thiop... | CAS号188290-36-0 Thiophene(SIV) | CAS号79-37-8 草酰氯 | CAS号104542-82-7 2-THIAZOLYL-2-T... | CAS号33955-17-8 [(噻吩-2-羰基)氨基]乙酸 | CAS号39098-97-0 2-噻吩乙酰氯 | CAS号5380-42-7 2-噻吩甲酸甲酯 | CAS号527-72-0 2-噻吩甲酸 | CAS号332163-01-6 4,5-二甲氧基-2-[(噻吩... | CAS号2810-04-0 噻吩-2-羧酸乙酯 | CAS号141946-05-6 1-噻吩-2-基-1,4-二氢... | CAS号14313-93-0 N,N-diethylthio... | CAS号4160-63-8 2-(4-甲氧基苄氧基)噻吩

2-噻吩甲酸置于草酰氯,三乙胺体系中,用 二氯甲烷 作为反应溶剂,化学反应 1.0H,反应生成 2-噻吩甲酰氯
参考文献:脒基和非脒基苯甲酰胺的合成和体外和体内抗凝和抗血小板活性
标题:脒基和非脒基苯甲酰胺的合成和体外和体内抗凝和抗血小板活性
摘要:合成了三种脒基和十种非脒基苯甲酰胺,作为基于 3-氨基苯甲酸支架的抗凝剂和抗血小板化合物.通过筛选体外活化部分凝血活酶时间 (Aptt) 和凝血酶原时间 (Pt) 的延长,初步评估了 13 种合成化合物 1-13,2B 和 3B 作为前药的抗凝活性.从获得的 Aptt 结果,两种脒基苯甲酰胺,N-(3'-脒基苯基)-3-(噻吩-2''-基羰基氨基)苯甲酰胺 (1,33.2 +/-0.7 S) 和 N-(4'-脒基苯基)-3-选择 (噻吩-2''-基羰基氨基) 苯甲酰胺 (2,43.5 +/-0.6 S) 来研究进一步的抗凝和抗血小板活性.1 (33.2 +/-0.7 S) 和 2 (43.5 +/-0.6 S) 的 Aptt 结果与体外 30 μm 的肝素 (62.5 +/-0.8 S) 进行了比较.我们研究了 1 和 2 对小鼠血液抗凝活性(离体)和尾部出血时间(体内)的影响.切尾/流血时间测定表明,1
DOI:10.3390/molecules21050676

专利信息

专利号:US-2004249170-A1
优先权日:2002-01-24
标 题 :Process for preparing an intermediate useful for the asymmetric synthesis of duloxetine
发明人：BORGHESE ALFIO
摘要:This invention provides a process for the synthesis of(S)-3-Methylamino-1-2-thienyl)-1-propanol, a key intermediate in the synthesis of duloxetine.

专利号:US-6608196-B2
优先权日:2001-05-03
标题 :Process for solid supported synthesis of pyruvate-derived compounds
发明人：WANG BING; JANAGANI SATYANARAYANA; CALLAWAY WYETH B; SESSLER JONATHAN L
权利人:GALILEO PHARMACEUTICALS INC
摘要:Provided are processes for synthesizing structurally diverse pyruvate-derived compounds using a parallel approach on a solid phase support. Examples of such a solid phase support include resins which have also been used in solid phase peptide synthesis.

专利号:US-2007015798-A1
优先权日:2005-02-25
标 题 :Efficient and stereoselective process for large scale synthesis of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-one derivatives
发明人：LI XUN; LEMAIRE SEBASTIEN; MARKO ISTVAN; WILLEMSENS ALBERT
权利人:LI XUN; LEMAIRE SEBASTIEN; MARKO ISTVAN; WILLEMSENS ALBERT
摘要:This invention relates to an efficient process for large scale stereoselective production of (3R)-3-(2,3-dihydrobenzofuran-5-yl)-1,2,3,4-tetrahydropyrrolo[3,4-b]quinolin-9-ones and key intermediates used for the preparation of benzofuranyl pyrroloquinolones as potent and selective PDE5 inhibitors for the treatment of erectile dysfunction, as well as pharmaceutical compositions and methods of treatment utilizing these compounds.

专利号:US-11981648-B2
优先权日:2019-06-13
标题:Method for the synthesis of 3-R-1,4,2-dioxazol-5-ones
发明人：HALL DAVID S; DAHN JEFFERY RAYMOND; HYNES TOREN
权利人:TESLA INC; PANASONIC HOLDINGS CORP
摘要:Provided are methods of preparing 3-R-1,4,2-dioxazol-5-one compounds using convenient and efficient methods. Also provided are 3-R-1,4,2-dioxazol-5-one compounds produced using the methods described.

专利号:US-4835280-A
优先权日:1985-01-18
标 题 :Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles
发明人：MARTENS ALFRED; HOELCK JENS-PETER; BERGER HERBERT; MUELLER-BECKMAN BERND; STREIN KLAUS; ROESCH EGON
权利人:BOEHRINGER MANNHEIM GMBH
摘要:The present invention provides Indolines of the formula: (II) (III) ps useful to provide pharmaceutically active pyrrolobenzimidazoles or tautomers thereof, of the formula: (I) These compounds are useful for treating heart or circulatory diseases, especially those which respond to a change of blood pressure, an increase in cardiac output and/or a change in micro-circulation.

专利号:US-7034154-B2
优先权日:1999-08-10
标 题:Synthesis of substituted pyrazolopyrimidines
发明人：GROSS RAYMOND S; WILCOXEN KEITH M; OGLESBY RICHARD CHRISTOPHER
权利人:NEUROCRINE BIOSCIENCES INC
摘要:Methods of making substituted pyrazolopyrimidines generally and, more particularly, N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide. Such compounds have utility over a wide range of indications, including treatment of insomnia. In the practice of the present invention, improved techniques which do not require use and/or isolation of the pyrazole intermediate are disclosed, as well as improved techniques for making the reaction intermediates themselves. Such techniques offer significant advantages, including enhanced efficiency, particularly in the context of large scale manufacture.